Answers are grounded in this paper and cite their sources.
Purpose: Patients with large estrogen receptor (ER)-positive, HER2-negative breast cancers have low pathologic complete response (pCR) rates with neoadjuvant chemotherapy. We aimed to determine the rate of tumor downstaging with concurrent neoadjuvant chemo-endocrine therapy (CET) compared with neoadjuvant chemotherapy (CT) in clinical stage 2/3 breast cancer. Methods: This phase II trial randomized women with operable grade 2-3, ER+/HER2- tumors with a primary >20mm 2:1 to neoadjuvant chemotherapy plus concurrent letrozole, or chemotherapy alone. Primary outcome was proportion of tumors down-staged to ≤20mm and ypT0-1ypN0/stage 0-1A. Evaluation of tumor infiltrating lymphocytes (TILs), RNA and DNA sequencing were performed to identify correlates of response. Results: ELIMINATE randomized 134 women, with 122 evaluable for the primary outcome. 24% (19/81) with CET and 20% (8/41) with CT (difference 3.9%, 95% CI -11% to 19%) achieved downstaging to ypT0-1ypN0. Overall, 6/122 (5%) had a pCR, all in the CET arm. MRI response was seen in 79% (CET), 66% (CT). Considering grade 3 tumors, 5/22 (23%) in the CET arm and 0/10 in the CT arm achieved pCR. Translational analyses revealed that pCR and RCB 0–I responses were enriched in baseline tumors with higher grade, higher TILs, elevated TMB, and immune activation signatures, independently of treatment arm. Conclusion: CET did not significantly increase downstaging to stage 0-IA. Exploratory analyses suggest a subset of high-grade ER+/HER2- tumors enriched for immune activity, with elevated TILs and high TMB, were associated with favourable response irrespective of treatment assignment. These findings support further exploration of immune-genomic biomarkers in future studies of ER+/HER2- breast cancer.
No takes yet. Share an insight, caveat, or question.
Murray et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: